查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1981505

子宫内膜癌治疗市场：2026年至2032年全球市场预测（依治疗方法、药物类别、治疗阶段、给药部位及给药途径划分）

Endometrial Cancer Treatment Market by Treatment Type, Drug Class, Line Of Therapy, Administration Setting, Mode Of Administration - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，子宫内膜癌治疗市场价值将达到 93.8 亿美元，到 2026 年将成长至 99.3 亿美元，到 2032 年将达到 157.7 亿美元，复合年增长率为 7.69%。

主要市场统计数据
基准年 2025 93.8亿美元
预计年份：2026年 99.3亿美元
预测年份：2032年 157.7亿美元
复合年增长率 (%) 7.69%

简要说明了临床实践、诊断和医疗保健服务的最新进展，这些进展正在改变当今子宫内膜癌的治疗模式。

子宫内膜癌的治疗正在经历一场快速的变革时期，无论在临床层面还是操作层面，这都得益于分子层面的深入研究、治疗方法的进步以及医疗服务体系的变革。肿瘤谱分析和基于生物标记的治疗选择技术的进步重塑了诊断流程，使临床医生不再仅仅依赖组织学检查，而是转向精准医疗模式，从而指导全身治疗方案的选择。同时，免疫调节疗法和标靶治疗相结合的联合治疗为以往治疗选择有限的患者拓展了治疗选择。此外，微创手术技术和前哨淋巴结定位技术降低了手术全期併发症，并缩短了患者的復原时间。

对模式转移创新、生物标记主导策略以及医疗保健去中心化进行分析概述，这些正在重新定义子宫内膜癌的治疗途径。

子宫内膜癌的治疗现状正经历着一场变革，其驱动力包括精准肿瘤学、联合免疫疗法、不断完善的手术标准以及医疗服务的去中心化。分子分层提高了错配修復（MMR）状态和特定标靶突变等生物标记的重要性，影响临床试验的设计，并扩大了标靶治疗的适用人群。同时，针对PD-1抑制剂和CTLA-4（通常与抗血管生成药物和标靶治疗联合使用）的治疗策略的兴起，预示着治疗方案正朝着多药联合全身治疗的方向发展，旨在使更多患者获得持续的疗效。

本报告冷静地评估了 2025 年实施的关税主导贸易措施将如何影响治疗和诊断管道的供应链韧性、筹资策略和临床连续性。

美国2025年实施的关税措施为整个子宫内膜癌治疗系统带来了一系列复杂的挑战和调整，影响了供应链、临床运作和筹资策略。部分进口药品原料、诊断试剂和医疗设备关税的提高，导致一些医疗机构和供应商的直接采购成本增加。为应对这项挑战，采购团队加快了供应商多元化，探索了替代采购合同，并加强了与国内生产合作伙伴的协作，以降低关税波动带来的风险。同时，各机构也努力维持临床试验的连续性，避免临床实验药物供应中断。

深入分析治疗方法、药物类别、治疗方案、给药途径和临床环境等细节，为研发和商业化决策提供支援。

在子宫内膜癌治疗整体，明确治疗细分对于将临床创新转化为营运和商业优先事项至关重要。治疗方法细分包括化疗、联合治疗、荷尔蒙疗法、免疫治疗、放射线治疗、手术和标靶治疗，每种疗法在研发、给药和报销方面都存在不同的考量。依药物类别进行详细分类，可以进一步扩展此观点，区分抗血管新生疗法、化疗药物、荷尔蒙疗法、免疫疗法和标靶治疗。此外，还可以进行亚细分，含铂类药物和紫杉烷类药物列为化疗药物的亚类，将Aromatase抑製剂和孕激素列为荷尔蒙疗法的亚类，将CTLA-4抑製剂和PD-1抑製剂列为免疫治疗的亚类，将mTOR抑製剂、PARP抑製剂和蛋白酪氨酸激酶抑製剂列为标靶治疗的亚类。依治疗线进行细分，可捕捉第一线、二线、三线、四线及后续临床序列的背景，进而决定临床实验终点、对照组选择及支付方解释。

反映细微区域差异的见解解释了法规结构、诊断基础设施和报销模式如何影响世界各地市场的治疗机会。

区域趋势对子宫内膜癌治疗和诊断的获取管道、监管重点和普及率有显着影响。在美洲，监管机构和支付者优先考虑卫生技术评估（HTA）和真实世界数据（RWE），同时许多医疗系统正在投资分子诊断能力和门诊输液中心，以改善医疗服务可近性并减少住院次数。这些区域性优先事项促进了在诊断网络完善的地区快速推广基于生物标记的治疗方法，但也凸显了在先进诊断服务获取仍然不均衡的地区存在的差距。

企业层面的策略观察强调，投资组合多元化、伙伴关係模式和诊断整合是该领域的关键竞争优势。

製药、生物技术、诊断和医疗设备公司的企业策略正朝着整合解决方案的方向发展，这些解决方案融合了新型疗法、伴随诊断和病患支援专案。主要企业致力于建立多元化的产品组合，力求在突破性免疫疗法和标靶治疗与成熟的治疗方法（如荷尔蒙疗法和细胞毒性疗法）之间取得平衡；而规模小规模的专业公司则专注于独特的作用机制和生物标誌物主导的适应症。伙伴关係和策略联盟日益专注于共同开发联合治疗、共同设计临床试验以加速向监管机构提交证据，以及透过许可协议扩大地域覆盖范围。

为领导者提供切实可行的建议，以加强诊断、实现供应链多元化、优化临床策略并协调支付方合作，从而确保医疗服务的可近性和影响力。

产业领导者应优先进行一系列合作，在管控营运和市场进入风险的同时，将临床创新转化为对病患持久的益处。首先，投资强大的分子诊断项目和伙伴关係，以确保在生物标记主导疗法中准确筛选患者。这包括支援病理检测基础设施和报销管道的建设，以避免诊断瓶颈。其次，制定临床开发计划，评估第一线及后续治疗方案（包括治疗顺序和联合治疗） ，同时纳入患者报告结局（PRO）和真实世界数据（REW）的收集，并加强其在支付方咨询和指南制定中的地位。

为了透明地说明检验收集和三角验证的过程，整合临床文献、註册资讯、相关人员访谈和营运分析，以得出严谨的结论。

本分析所依据的研究结合了对监管指南、同行评审的临床文献和公共临床实验室註册资料的系统性回顾，以及对临床医生、支付方、诊断领域领导者和商业领域高管的专家访谈。二手资料提供了关于治疗机制、近期核准和指南变更以及外科治疗和门诊护理进展的背景资讯。一手研究透过与熟悉临床实验室设计、检查室运作、医院采购和支付方决策的相关人员进行定性对话，检验了策略假设，并将临床趋势与实际情况进行了比对。

最终结论是将临床创新和营运要求相结合，为改善所有护理路径中的患者预后提供一致的愿景。

总之，子宫内膜癌的治疗格局呈现出一种建设性的张力：一方面是快速的临床创新，另一方面是将这些创新成果惠及病患所需的复杂运作流程。基于生物标记的患者筛选、免疫疗法与标靶治疗的联合应用，以及手术和门诊管理的改进，都在拓展治疗的可能性，同时也要求制定侧重于新型诊断方法、物流以及与保险公司合作的策略。同时，贸易政策的变化和区域基础设施的差异等外部因素，也要求製药公司、医疗服务提供者和保险公司做出务实的调整，以确保临床检测的可近性和连续性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 子宫内膜癌治疗市场：依治疗方法

  • 化疗
  • 联合治疗
  • 荷尔蒙疗法
  • 免疫疗法
  • 放射线治疗
  • 外科手术
  • 分子标靶治疗

第九章 子宫内膜癌治疗市场：依药物类别划分

  • 抗血管新生疗法
  • 化疗药物
    • 含铂类药物
    • 紫杉烷类药物
  • 荷尔蒙疗法
    • Aromatase抑制剂
    • 黄体素
  • 免疫疗法
    • CTLA-4抑制剂
    • PD-1抑制剂
  • 标靶治疗
    • mTOR抑制剂
    • PARP抑制剂
    • 蛋白酪氨酸激酶抑制剂

第十章 子宫内膜癌治疗市场：依治疗阶段划分

  • 第 1 行
  • 从第四行开始
  • 第二行
  • 第三行

第十一章 子宫内膜癌治疗市场：依医疗机构划分

  • 门诊治疗
  • 住院病人
  • 门诊医院

第十二章 子宫内膜癌治疗市场：依给药途径划分

  • 静脉注射
  • 口服

第十三章 子宫内膜癌治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 子宫内膜癌治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 子宫内膜癌治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国子宫内膜癌治疗市场

第十七章：中国子宫内膜癌治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Context Therapeutics Inc.
  • CooperSurgical Inc.
  • Eisai Co., Ltd.
  • Elekta AB
  • F. Hoffmann-La Roche AG
  • General Electric Company
  • GlaxoSmithKline PLC
  • Hologic Inc.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Koninklijke Philips NV
  • LiNA Medical ApS
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-521BAA36EC26

The Endometrial Cancer Treatment Market was valued at USD 9.38 billion in 2025 and is projected to grow to USD 9.93 billion in 2026, with a CAGR of 7.69%, reaching USD 15.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.38 billion
Estimated Year [2026] USD 9.93 billion
Forecast Year [2032] USD 15.77 billion
CAGR (%) 7.69%

A concise introduction that contextualizes recent clinical, diagnostic, and care delivery advancements reshaping endometrial cancer treatment paradigms today

Endometrial cancer care has experienced an accelerated period of clinical and operational change driven by molecular insights, therapeutic innovation, and shifts in care delivery. Advances in tumor profiling and biomarker-driven treatment selection have reframed diagnostic pathways, enabling clinicians to move beyond histology alone toward precision approaches that guide systemic therapy choices. At the same time, combination regimens that pair immune modulation with targeted agents have expanded therapeutic options for patients who previously had limited choices, while minimally invasive surgical techniques and sentinel node mapping have reduced perioperative morbidity and shortened recovery timelines.

Transitioning from discovery to adoption, stakeholders across clinical, regulatory, and payer communities are aligning around evidence frameworks that emphasize meaningful clinical benefit and real-world effectiveness. Consequently, health systems and providers are adapting workflows to integrate outpatient-friendly administration modes and patient-reported outcome monitoring. These changes demand coordinated shifts in clinical operations, diagnostics infrastructure, and commercial strategies to ensure that innovations translate into improved patient outcomes and sustainable care pathways.

An analytical overview of paradigm-shifting innovations, biomarker-driven strategies, and care decentralization that are redefining endometrial cancer treatment pathways

The landscape of endometrial cancer treatment is undergoing transformative shifts driven by precision oncology, immunotherapy combinations, evolving surgical standards, and the decentralization of care. Molecular stratification has elevated the role of biomarkers such as mismatch repair status and specific actionable mutations, which in turn has influenced clinical trial design and broadened the population eligible for targeted interventions. Concurrently, the rise of PD-1 inhibitors and CTLA-4-directed strategies, often combined with antiangiogenic or targeted agents, illustrates a shift toward multimodal systemic regimens that seek to convert durable responses in a greater proportion of patients.

In parallel, care delivery is moving toward more outpatient-friendly models supported by oral targeted therapies and improved supportive care that reduce hospital stays. Surgical practice continues to evolve with less invasive approaches and enhanced recovery protocols that preserve quality of life. These dynamics are reinforcing cross-disciplinary collaborations among medical oncology, gynecologic surgery, radiation oncology, and molecular pathology. As a result, stakeholders are increasingly focused on evidence generation around combinatorial approaches, sequencing strategies across first line and subsequent lines of therapy, and the value proposition of precision diagnostics to guide therapeutic selection.

A clear-eyed assessment of how tariff-driven trade measures in 2025 have reshaped supply chain resilience, procurement strategies, and clinical continuity across treatment and diagnostic channels

The implementation of United States tariffs in 2025 has introduced a complex set of headwinds and adaptive responses across the endometrial cancer treatment ecosystem, touching supply chains, clinical operations, and procurement strategies. Increased duties on specific imported pharmaceutical components, diagnostic reagents, and medical devices have elevated direct procurement costs for some institutions and suppliers. In turn, procurement teams have accelerated supplier diversification, sought alternative sourcing agreements, and engaged more deeply with domestic manufacturing partners to mitigate exposure to tariff volatility. These operational adjustments have unfolded alongside efforts to preserve continuity of clinical trials and avoid interruptions to investigational agent supply.

Moreover, the tariffs have intensified scrutiny over inventory management and contractual terms across distributor networks, prompting stakeholders to renegotiate long-term agreements and to consider hedging strategies for critical consumables. Regulatory interactions and customs clearance processes have required closer coordination between manufacturers and supply chain partners to reduce lead times. Importantly, clinicians and health system leaders have focused on maintaining patient access by prioritizing treatment pathways that leverage locally produced agents or oral formulations less vulnerable to cross-border logistics constraints. Collectively, these adaptations reflect the sector's pragmatic approach to preserving treatment continuity and clinical research momentum in the face of evolving trade policy.

Deep segmentation-focused insights that connect treatment types, drug classes, lines of therapy, administration modes, and care settings to inform development and commercialization choices

Segmentation clarity is critical to translating clinical innovation into operational and commercial priorities across endometrial cancer care. Treatment type segmentation encompasses chemotherapy, combination therapy, hormone therapy, immunotherapy, radiation therapy, surgery, and targeted therapy, each of which presents different development, administration, and reimbursement considerations. Drug class granularity extends this view by distinguishing antiangiogenic therapy, chemotherapeutic agents, hormonal therapy, immunotherapy, and targeted therapy, with further subcategorization that highlights platinum based agents and taxanes under chemotherapeutics, aromatase inhibitors and progestins under hormonal therapy, CTLA-4 inhibitors and PD-1 inhibitors under immunotherapy, and mTOR inhibitors, PARP inhibitors, and tyrosine kinase inhibitors under targeted therapy. Line of therapy segmentation captures the clinical sequencing context across first line, second line, third line, and fourth line and beyond, which dictates trial endpoints, comparator selection, and payer narratives.

Mode of administration, separated into intravenous and oral delivery, informs site-of-care planning, adherence strategies, and patient support services. Meanwhile, administration setting-ambulatory care, hospital inpatient, and hospital outpatient-shapes operational workflows, capital requirements, and the economics of care delivery. Integrating these segmentation lenses enables stakeholders to pinpoint evidence gaps, prioritize development portfolios for specific clinical contexts, and design commercial models that reflect how treatments are used across real-world practice settings.

Regionally nuanced intelligence that explains how regulatory frameworks, diagnostic infrastructure, and reimbursement models influence therapeutic access across global markets

Regional dynamics exert a strong influence on access pathways, regulatory priorities, and adoption rates for endometrial cancer therapeutics and diagnostics. In the Americas, regulatory authorities and payers emphasize health technology assessment and real-world evidence, while many systems invest in molecular diagnostic capacity and outpatient infusion centers to improve access and reduce hospitalization. These regional priorities have supported rapid uptake of biomarker-driven treatments in settings with established diagnostic networks, but they have also underscored disparities where access to advanced diagnostics remains uneven.

Across Europe, Middle East & Africa, variations in national reimbursement frameworks, diagnostic infrastructure, and clinical guideline harmonization drive differentiated adoption. Stakeholders in these markets have placed emphasis on cross-border clinical collaborations, centralized pathology review for trial enrollment, and capacity building for precision diagnostics. In the Asia-Pacific region, accelerated investment in domestic biopharmaceutical capabilities, public-private partnerships, and expanding clinical trial activity have supported faster localization of novel agents. However, differences in regulatory pathways, pricing policies, and reimbursement timelines require tailored market entry strategies and adaptive evidence-generation plans to secure sustainable access across distinct national environments.

Strategic company-level observations that highlight portfolio diversification, partnership models, and diagnostic integration as key competitive differentiators in the sector

Corporate strategies across pharmaceutical, biotechnology, diagnostic, and device companies are converging on integrated solutions that pair novel therapeutics with companion diagnostics and patient support programs. Leading organizations focus on building diversified portfolios that balance transformational immunotherapies and targeted agents with established modalities such as hormonal and cytotoxic therapies, while smaller specialized firms concentrate on niche mechanisms and biomarker-driven indications. Partnerships and strategic alliances increasingly center on co-development of combination regimens, jointly designed trials that accelerate regulatory evidence, and licensing agreements that extend geographic reach.

In addition, contract research organizations and diagnostic manufacturers have intensified collaboration with sponsors to streamline trial enrollment through centralized testing and harmonized biomarker panels. Commercial teams are also evolving their engagement models to emphasize value communication toward payers and integrated delivery networks, leveraging health economic modeling and real-world data to substantiate comparative benefit. Across the competitive landscape, agility in clinical development, capabilities in companion diagnostics, and a demonstrated ability to negotiate access agreements will continue to separate market leaders from followers.

Action-oriented recommendations that guide leaders to strengthen diagnostics, diversify supply chains, optimize clinical strategies, and align payer engagement to secure access and impact

Industry leaders should prioritize a coordinated set of actions to translate clinical innovation into durable patient impact while managing operational and market access risks. First, invest in robust molecular diagnostic programs and partnerships to ensure accurate patient selection for biomarker-driven therapies; this includes supporting pathology capacity building and reimbursement pathways to avoid diagnostic bottlenecks. Next, design clinical development plans that evaluate sequencing and combinations across first-line and later lines of therapy, while embedding patient-reported outcomes and real-world evidence collection to strengthen payer discussions and guideline positioning.

Operationally, diversify supply chains and cultivate regional manufacturing partnerships to reduce tariff and logistical exposure, and adopt inventory strategies that preserve trial continuity. Commercially, develop value communication strategies that stress clinical differentiation, health economic impact, and adherence support, particularly for oral therapies that shift care to ambulatory and outpatient settings. Finally, engage early with payers and regulatory authorities to co-create evidence frameworks that accelerate access decisions and to pursue adaptive reimbursement approaches tied to outcomes data. Implementing these steps will enhance organizational resilience and increase the probability that clinical advances yield meaningful benefits at scale.

A transparent description of the evidence gathering and triangulation process integrating clinical literature, registries, stakeholder interviews, and operational analysis to produce rigorous insights

The research underpinning this analysis combined a structured review of regulatory guidance, peer-reviewed clinical literature, public clinical trial registries, and expert interviews with clinicians, payers, diagnostics leaders, and commercial executives. Secondary sources provided context on therapeutic mechanisms, recent approvals and guideline changes, and advances in surgical and outpatient care. Primary research validated strategic hypotheses through qualitative dialogues with stakeholders experienced in trial design, laboratory operations, hospital procurement, and payer decision-making, enabling triangulation of clinical trends with operational realities.

Data synthesis employed a thematic approach to map clinical innovations against care delivery models and regional access constraints. Methodological rigor included cross-validation of clinical endpoints, therapy sequences, and diagnostic dependencies, as well as sensitivity to policy and tariff shifts that affect supply chains. Limitations of the methodology include reliance on available public clinical data and stakeholder perspectives at a particular point in time; consequently, the analysis emphasizes evidence-based insights and actionable implications rather than speculative projections.

A definitive conclusion that synthesizes clinical innovations and operational imperatives into a coherent outlook for delivering improved patient outcomes across care pathways

In conclusion, the treatment landscape for endometrial cancer is characterized by a productive tension between rapid clinical innovation and the operational complexities required to deliver those advances to patients. Biomarker-driven selection, immunotherapy and targeted agent combinations, and improvements in surgical and outpatient management are converging to broaden therapeutic possibilities and to demand new diagnostic, logistical, and payer-aligned strategies. At the same time, external factors such as trade policy shifts and regional infrastructure variability require pragmatic adaptations by manufacturers, providers, and payers to safeguard access and clinical trial continuity.

Looking forward, success will accrue to organizations that integrate robust diagnostic capabilities, pursue rational combination and sequencing trials, and align commercial models with evolving care settings. By balancing scientific ambition with operational resilience and payer collaboration, stakeholders can convert promising clinical innovations into measurable improvements in patient outcomes and system sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Endometrial Cancer Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Combination Therapy
  • 8.3. Hormone Therapy
  • 8.4. Immunotherapy
  • 8.5. Radiation Therapy
  • 8.6. Surgery
  • 8.7. Targeted Therapy

9. Endometrial Cancer Treatment Market, by Drug Class

  • 9.1. Antiangiogenic Therapy
  • 9.2. Chemotherapeutic Agents
    • 9.2.1. Platinum Based Agents
    • 9.2.2. Taxanes
  • 9.3. Hormonal Therapy
    • 9.3.1. Aromatase Inhibitors
    • 9.3.2. Progestins
  • 9.4. Immunotherapy
    • 9.4.1. CTLA-4 Inhibitors
    • 9.4.2. PD-1 Inhibitors
  • 9.5. Targeted Therapy
    • 9.5.1. MTOR Inhibitors
    • 9.5.2. PARP Inhibitors
    • 9.5.3. Tyrosine Kinase Inhibitors

10. Endometrial Cancer Treatment Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Fourth Line And Beyond
  • 10.3. Second Line
  • 10.4. Third Line

11. Endometrial Cancer Treatment Market, by Administration Setting

  • 11.1. Ambulatory Care
  • 11.2. Hospital Inpatient
  • 11.3. Hospital Outpatient

12. Endometrial Cancer Treatment Market, by Mode Of Administration

  • 12.1. Intravenous
  • 12.2. Oral

13. Endometrial Cancer Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Endometrial Cancer Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Endometrial Cancer Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Endometrial Cancer Treatment Market

17. China Endometrial Cancer Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AstraZeneca PLC
  • 18.7. Bayer AG
  • 18.8. Becton, Dickinson and Company
  • 18.9. Boston Scientific Corporation
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Celgene Corporation
  • 18.12. Context Therapeutics Inc.
  • 18.13. CooperSurgical Inc.
  • 18.14. Eisai Co., Ltd.
  • 18.15. Elekta AB
  • 18.16. F. Hoffmann-La Roche AG
  • 18.17. General Electric Company
  • 18.18. GlaxoSmithKline PLC
  • 18.19. Hologic Inc.
  • 18.20. Johnson & Johnson Services, Inc.
  • 18.21. Karyopharm Therapeutics Inc.
  • 18.22. Koninklijke Philips N.V.
  • 18.23. LiNA Medical ApS
  • 18.24. Merck & Co., Inc.
  • 18.25. Novartis AG
  • 18.26. Pfizer Inc.
  • 18.27. Sanofi S.A.
  • 18.28. Siemens Healthineers AG
  • 18.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 202. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 232. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 237. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 242. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)